Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quinapril + hydrochlorothiazide is a fixed-dose combination medication used to treat high blood pressure (hypertension). It contains two active ingredients: - Quinapril, an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II. This leads to relaxation of blood vessels and reduced blood pressure by inhibiting vasoconstriction and decreasing aldosterone-mediated sodium and fluid retention. - Hydrochlorothiazide, a thiazide diuretic ("water pill") that increases urine output by promoting renal excretion of sodium and water. This reduces plasma volume and helps lower blood pressure. The combination provides greater antihypertensive effects than either agent alone. Lowering high blood pressure with this medication reduces the risk of stroke, heart attack, heart failure, kidney failure, and other complications associated with hypertension[1][2][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quinapril + hydrochlorothiazide.